SIGA Technologies, Inc. Q3 2025 Earnings Recap

SIGA Technologies reported a solid third quarter, with product revenues totaling approximately $86 million year-to-date, reflecting continued government engagement for smallpox antiviral procurement amid evolving bioterrorism concerns.

Key Takeaways

• Year-to-date product revenue was approximately $86 million, driven by strong oral and IV TPOXX sales.
• Approximately $26 million in outstanding U.S. government orders, primarily for IV TPOXX, expected to be delivered in 2026.
• Ongoing discussions regarding future procurement of TPOXX highlight the U.S. government's commitment to bioterrorism preparedness amidst a pending government shutdown.
• SIGA is progressing on pediatric formulation development and an FDA submission for post-exposure prophylaxis (PEP) planned for 2026, despite some delays due to the shutdown.
• International sales opportunities are anticipated for 2026 as global health security strategies evolve in response to bioterrorism threats.